AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Drug development company doses first patient in breast cancer study.
2004 MAY 6 - (NewsRx.com & NewsRx.net) -- YM BioSciences Inc. (YM) announced that the first patient has been dosed in its 700-patient phase III registration trial for metastatic breast cancer.
The international pivotal trial is designed to compare the overall survival differential resulting from the combination of YM's drug, tesmilifene, with the anthracycline, epirubicin, and cyclophosphamide against the use of epirubicin/cyclophosphamide alone in women with metastatic breast cancer.
"We are very pleased to have commenced this important trial on time, and anticipate to have completed enrolment in approximately 18 months," said Mr. David Allan, chairman and chief executive officer of YM BioSciences.
Tesmilifene is a small molecule chemopotentiator. In the first phase III trial, which enrolled 305 women, overall survival in women on the combination of tesmilifene with anthracycline (the standard of care in metastatic breast cancer) was greater than 50% longer than for women treated with the standard of care alone.
The drug has been clinically demonstrated to increase the effectiveness of the current principal chemotherapeutic drugs, anthracyclines and taxanes, ...
- Frost & Sullivan Names YM BioSciences 2004 Breast Cancer Therapies...
- Press release article from: Business Wire May 5, 2004 700+ words
...entitled "U.S. Breast Cancer Therapeutics Market...Sullivan found that YM BioSciences (TSX:YM...against cancer. YM BioSciences' pipeline focuses...as metastatic breast cancer, prostate cancer...with the FDA, YM BioSciences is the recipient...Sullivan's ...
- YM BioSciences doses first patient in pivotal breast cancer study.
- Press release article from: PR Newswire March 31, 2004 700+ words
...women with metastatic breast cancer. "We are very pleased...Chairman and CEO of YM BioSciences. Tesmilifene is a...care in metastatic breast cancer) was greater than...America and Europe. YM BioSciences may be able to submit...
- YM BioSciences receives FDA fast track designation for tesmilifene in advanced...
- Press release article from: PR Newswire February 13, 2006 700+ words
...with advanced breast cancer. While the...confirms that YM BioSciences' lead drug...recurrent breast cancer. The Fast Track...and recurrent breast cancer. Separately...cancer. About YM BioSciences YM BioSciences...
- YM BioSciences Cleared by FDA to Initiate Phase III Registrational Trial for...
- Press release article from: PR Newswire November 4, 2003 700+ words
...with metastatic breast cancer, as the drug...Chairman and CEO of YM BioSciences. "The incorporation...recurrent breast cancer patients receiving...from aggressive breast cancer, defined as...increase. About YM BioSciences YM BioSciences...
- YM BioSciences announces termination of the tesmilifene Phase III pivotal trial...
- Press release article from: PR Newswire January 30, 2007 700+ words
...FirstCall/ -- YM BioSciences Inc. , an oncology...metastatic or recurrent breast cancer has completed...Shaughnessy, a leading breast cancer researcher, oncologist...high praise to YM BioSciences. The DSMB is...designation for advanced breast cancer by the ...
- YM BioSciences cleared by FDA to initiate Phase III registrational trial for...
- News wire article from: Asia Africa Intelligence Wire November 4, 2003 700+ words
...Business NewsBase - Press Release) YM BioSciences Inc has received written confirmation...advanced metastatic/recurrent breast cancer patients receiving tesmilifene...traditional chemotherapy agents. YM BioSciences Inc is a cancer drug development...
- YM BioSciences reports third quarter 2004 results.
- Press release article from: PR Newswire May 27, 2004 700+ words
...amp; Sullivan declared YM BioSciences the 2004 Breast Cancer Therapies Entrepreneurial...2005 fiscal year. About YM BioSciences YM BioSciences Inc. is a cancer drug...III trial in metastatic breast cancer, which was initiated...
- YM BioSciences announces update on tesmilifene pivotal trial.
- News wire article from: Chemical Business Newsbase June 7, 2006 700+ words
...Press Release) YM BioSciences Inc advises that...metastatic and recurrent breast cancer has occurred. The...targets are achieved. YM BioSciences has received FDA...tesmilifene in advanced breast cancer. YM BioSciences Inc is a company...
- YM BioSciences Lead Drug Subject of Journal Publication.
- Press release article from: PR Newswire January 29, 2004 700+ words
...with metastatic breast cancer treated with our...Executive Officer of YM BioSciences. "We anticipate...also in metastatic breast cancer. The primary endpoint...with aggressive breast cancer. About YM BioSciences YM BioSciences...
- YM BioSciences' lead drug subject of journal publication. NCIC Phase III trial...
- News wire article from: Asia Africa Intelligence Wire January 29, 2004 700+ words
...study showed that YM BioSciences' lead drug, tesmilifene...metastatic or recurrent breast cancer. Specifically...also in metastatic breast cancer. The primary endpoint...with aggressive breast cancer. YM BioSciences Inc is a cancer...
Source: HighBeam Research, Drug development company doses first patient in breast cancer study.